Whistleblower Rule Encourages Internal Reporting Of Violations
This article was originally published in The Rose Sheet
Whistleblowers have new incentives to report violations to their company's internal compliance program rather than directly to the Securities and Exchange Commission under a final rule the agency recently adopted.
You may also be interested in...
CDRH Director Jeffrey Shuren discussed the device center’s two-year strategic priorities with “The Gray Sheet.” The center plans to rebalance pre-market and post-market data collection, when appropriate, and improve the processes for starting up clinical trials in the U.S.
In a long-awaited final guidance, FDA affirmed its plan to practice enforcement discretion for most mobile medical apps, except those applications that present the same risks as conventional FDA-regulated devices. Some digital health stakeholders praised the guidance, while others wished FDA had waited.
The proposed surveillance program would test marketed blood glucose monitor systems to ensure they are performing at the level expected when they were cleared. It was met with support from FDA, device companies, academics and patient advocates.